US Patent Issued to Arrowhead Pharmaceuticals on Aug. 5 for "RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use" (California, Wisconsin Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,558, issued on Aug. 5, was assigned to Arrowhead Pharmaceuticals Inc. (Pasadena, Calif.).

"RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use" was invented by Xiaokai Li (San Diego), Tao Pei (Middleton, Wis.), Casi Schienebeck (Deerfield, Wis.), Yichen Wang (San Diego), Zhi-Ming Ding (Waunakee, Wis.) and Grigoriy Shekhtman (Los Angeles).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use ...